EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Insmed's enterprise value is $4,125.5 Mil.
Insmed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-660.2 Mil. Therefore, Insmed's EV-to-EBITDA for today is -6.25.
The historical rank and industry rank for Insmed's EV-to-EBITDA or its related term are showing as below:
INSM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.01 Med: -8.25 Max: -3.27
Current: -6.25
During the past 13 years, the highest EV-to-EBITDA of Insmed was -3.27. The lowest was -20.01. And the median was -8.25.
INSM's EV-to-EBITDA is ranked worse than 100% of 470
companies
in the Biotechnology industry
Industry Median: 9.14
vs INSM: -6.25
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-26), Insmed's stock price is $24.72.
Insmed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.340. Therefore, Insmed's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Insmed EV-to-EBITDA Historical Data
The historical data trend for Insmed's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Insmed's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Insmed's EV-to-EBITDA falls into.
Insmed's current Enterprise Value is $4,125.5 Mil.
Insmed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-660.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (NAS:INSM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Insmed's share price for today is $24.72.
Insmed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Insmed's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your 